Table 1.
Clinical characteristics of the patients and the control group
| Characteristics | Value |
|---|---|
| AML group | |
| Number (n) | 79 |
| Age (year) | |
| Me | 59 |
| Range | 18–87 |
| Sex (female/male) | 37/42 |
| WBC (× 109/L) | |
| Me | 4.48 |
| Range | 0.54–252 |
| Hb (g/dL) | |
| Me | 8.4 |
| Range | 3.0–14.3 |
| PLT (x109/L) | |
| Me | 54 |
| Range | 6–586 |
| LDH (U/L) | |
| Me | 299 |
| Range | 163–3350 |
| BM blasts | (%) |
| Me | 47 |
| Range | 20–100 |
| Cytogenetic risk | n (%) |
|---|---|
| Favorable | 6 (7.6%) |
| Intermediate | 37 (46.8%) |
| Unfavorable | 25 (31.6%) |
| Unknown | 11 (13.9%) |
| Treatment | n (%) |
|---|---|
| Intensive | 38 (48.1%) |
| Non-intensive | 30 (38%) |
| HMA | 17 (21.5%) |
| LDAC | 13 (16.5%) |
| BSC | 11 (13.9%) |
| Number (n) | 23 |
|---|---|
| Control group | |
| Age (year) | |
| Me | 52 |
| Range | 21–76 |
| Sex (female/male) | 10/13 |
| Diagnosis | n (%) |
|---|---|
| DLBCL | 10 (43%) |
| HL | 4 (17%) |
| MCL | 3 (13%) |
| Others | 6 (26%) |
Me median, WBC white blood cells, Hb hemoglobin level, PLT platelets, LDH lactate dehydrogenase, SWOG Southwestern Oncology Group, HMA hypomethylating agents, LDAC low-dose arabinoside cytosine, DLBCL diffuse large B-cell lymphoma, HL Hodgkin lymphoma, MCL mantle cell lymphoma